Statins have been implicated in the regulation of cell proliferation, apoptosis and tumor progression in cancer patients and statin use at the time of cancer diagnosis has been reported to be associated with reduced cancer risk and improved survival, irrespective of concomitant anti-cancer therapy. A systematic literature search of relevant databases through May 2015 was conducted to identify studies assessing the prognostic impact of statin use on prognostic outcomes in cancer patients. Literature search identified 95 cohort studies that met the inclusion criteria. A meta-analysis of 55 articles showed that statin use was significantly associated with decreased risk of all-cause mortality (HR 0.70, 95% Cl 0.66 to 0.74) compared with nonusers. The observed pooled estimates were retained for cancer-specific mortality (HR 0.60, 95% Cl 0.47 to 0.77), progressionfree survival (HR 0.67, 95% Cl 0.56 to 0.81), recurrence-free survial (HR 0.74, 95% Cl 0.65 to 0.83) and disease-free survival (HR 0.53, 95% Cl 0.40 to 0.72). These associations almost remained consistent across those outcomes when stratified by publication type, tumour location, study design, sample size, initiation of statins, disease stage, research country, follow-up duration or research hospital involved. Subgroup analyses according to initiation of statins showed postdiagnosis statin users (HR 0.65, 95% Cl 0.54 to 0.79) gained significantly more recurrence-free survival benefit than prediagnosis statin users (HR 0.86, 95% Cl 0.77 to 0.96) (p for interaction 5 0.018). Statin therapy has potential survival benefit for patients with malignancy. Further large-scale prospective studies emphasising survival outcomes of individual cancer type are strongly encouraged.
According to the World Health Organization, cancers are among the leading causes of death worldwide, accounting for 8.2 million deaths in 2012, 1 which contributes substantially to healthcare budgets both in developed and developing countries. 2, 3 Statins (HMG-CoA reductase inhibitors), a class of widely prescribed cholesterol lowering agents, have shown anticancer properties beyond its cardiovascular benefits. [4] [5] [6] And such effects might be beneficial in the prevention of malignancy.
To date, a number of studies have investigated the prognostic role of the use of statins in patients diagnosed with cancer. Although some studies have reported positive prognostic value for cancer patients who take statins, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 32 results from several other studies were inconsistent. It has been found in several cancer types that statin use showed improved prognostic outcomes while still some other studies reported null prognostic value. [23] [24] [25] [27] [28] [29] [30] 33, 37 Previous studies indicated that statin use in patients with diagnosed cancer or before diagnosis of cancer has significant public health implications. 10, [38] [39] [40] A meta-analysis based on 22 randomized controlled trials showed that statin use was not associated with reduced cancer related mortality (hazard ratio [HR], 1.01; 95% confidence interval [CI] , 0.93-1.09) compared with nonstatin use. 41 However, it is unclear whether statins affect prognostic outcomes for patients with established malignancy. Recently Ahern et al. performed a review assessing the association between statin use and breast cancer recurrence and provided evidence that statins exerted a protective effect on breast cancer recurrence. 42 In addition, these reviews included studies with varying cancer types, study designs or follow-up duration, which provided limited data and conflicting scenario in terms of the prognostic benefits on established diagnosed malignancy. Moreover, the widespread use of such agents underlined an urgent need for the establishment of the complete prognostic profile of statins in cancer patients. Our primary purpose was to systematically determine the risk of cancer mortality and progression associated with the long-term use of statins compared with nonusers in patients with established malignancy.
Methods

Search strategy
Our study was conducted in accordance with the Preferred Reporting Items of Systematic reviews and Meta-Analyses (PRISMA) guidelines. 43 A systematic literature search of Pubmed, Embase, CENTRAL and American Society of Clinical Oncology (ASCO) databases was performed from inception through May 2015 with no language or publication type limitations to identify studies assessing the prognostic impact of statin use on survival outcomes in patients diagnosed with cancer. We also conducted a manual screen of reference cited in the retrieved articles, reviews and metaanalyses for additional studies. Unpublished studies were not searched. The following terms and text words used for the literature search were included: hydroxymethylglutaryl-CoA reductase inhibitors, neoplasms and prognosis/mortality/survival (as MeSH terms), combined with statins, cancer/ tumour/carcinoma/malignan* and survival outcomes (as text words in the title or abstract). The full literature search strategy is presented in Supporting Information Table 1 (available  online) .
Study selection and inclusion criteria
Two reviewers (Z.M. and M.L. or Y.Z.) independently selected and identified the appropriate studies based on the prespecified selection criteria. Discrepancies between the two reviewers were resolved by discussion or the senior author (W.Y. or L.L.). Observational studies were considered to be eligible if they satisfied the following criteria: (1) studies prospectively or retrospectively enrolled the patients who were clinically and pathologically diagnosed with malignancy. (2) studies reported the associations of statin therapy and one or more survival outcomes of interest, such as all-cause mortality (ACM), cancer-specific mortality (CSM), progression-free survival (PFS), recurrence-free survival (RFS) or disease-free survival (DFS); and (3) studies examining statin use in cancer patients at the time of, before or after cancer diagnosis irrespective of the other cancer treatment options and providing relevant patient survival data with a HR estimate and its 95% CI comparing statin users with nonusers, or indirect information such as Kaplan-Meier curves to estimate them using the methods described by Tierney et al. 44 and Parmar et al. 45 We excluded studies that did not contain survival outcomes, as well as studies with no original data. When duplicate publications of the same study were found, we used the dataset from the most informative one.
Data extraction and quality assessment Cancer Epidemiology the study was performed; publication type; study design; number of hospitals involved; site of disease; inclusion period; sample size; number of outcome events; initiation of statin use; stage of disease; country of origin; follow-up period; survival end points; HRs with corresponding 95% CIs and adjustment variables. A set of modified predefıned criteria for evaluating the quality of the studies was applied to assess the quality of the evidence on the association between statin use and the cancer outcomes for each study.
Definitions of study endpoints
The major study endpoint was ACM which was defined as the time from the study enrollment to death from any cause. The secondary endpoints included (1) CSM, defined as the time from the study enrollment to death from specific cancer; (2) PFS, defined as time from the study enrollment to first observed cancer progression or death occurred; (3) RFS, defined as the time from the study enrollment to the first documented disease recurrence or death from any cause, whichever happened first; and (4) DFS, defined as time from the study enrollment to disease recurrence, occurrence of a new primary cancer or death from any cause. Regular statin use was defined as statin prescriptions taken during the last 6 months and for 2 years before cancer diagnosis.
Statistical analyses
ACM was set as the major outcome of interest and secondary outcomes of interest included CSM, PFM, RFM and DFM for established cancer patients with regular statin use compared to those without statin use. The summary HRs with corresponding 95% CIs of each survival measure were quantitatively aggregated with the DerSimonian and Laird random effects model. 46 The between-study heterogeneity was examined by the Cochran's Q-test and I 2 statistic, with a p values for heterogeneity by the I 2 value >50% indicating substantial heterogeneity. 47 We also conducted subgroup analyses to explore the possible source of heterogeneity by analysing the potential influential factors that could explain the heterogeneity. The between-subgroup differences were investigated using the methods described by Deeks et al.
48
Publication bias was assessed by visual inspection of the funnel plot symmetry as well as by Begg's regression and Egger's linear regression test. 49, 50 Moreover, Duval's nonparametric trim and fill procedure was used to further assess the possible effect of publication bias. 51 All statistical analyses were performed using R software version 3. 
Results
Search and selection of studies
Of the 5,622 eligible citations in the initial literature search, 251 potentially relevant studies were screened for further review. After removing 156 studies, a total of 95 studies met the inclusion criteria and were included in the final analysis ( Fig. 1 and Supporting Information Table S2 ). Table S3 provide the basic and summarized characteristics of the identified studies that met the inclusion criteria. Fifty studies involved single centre data, whereas 41 were multicenter studies. Fifty-five studies were conducted in North America, 21 in Europe, eight in Asia and three covered multiple continents. Fifty-five studies investigated the association between statin use and ACM for cancer patients, whereas 75 studies reported the other outcomes (PFM, RFM and DFM). >18 malignancies were investigated in our study, among which prostate cancer, breast cancer and colorectal cancer were the three most common types of cancer involved. 34 studies evaluated nonmetastatic cancers, seven studies evaluated metastatic cancers and 43 studies evaluated mixed ones. Fifty-three studies involved patients who initiated statins before diagnosis of cancer and 32 involved patients who initiated statins after diagnosis of cancer. Sex, age at diagnosis, disease stage, body mass index, disease stage, tumour grade and adjuvant therapy are commonly examined covariates that were adjusted for in Cox's proportionalhazard model evaluation of the relationship between statin use and cancer outcomes.
Relationship between statin use and cancer outcomes
Meta-analysis of statin use and patient outcomes, subgroup analyses, analyses of publication bias with different models are presented in Table 2 and Table 3 .
All-cause mortality. Fifty-five studies with 485,250 individuals were involved in the analysis of statin use and ACM. The summary HR for the ACM comparing statin use versus nonuse was 0.70 (95% CI, 0.66 to 0.74, Fig. 2 ), among which prostate cancer (n 5 10; HR 0.72, 95% CI, 0.63 to 0.81), colorectal cancer (n 5 9; HR 0.76, 95% CI, 0.68 to 0.86) and breast cancer (n 5 7; HR 0.65, 95% CI, 0.43 to 0.99) were three commonest types of cancer involved (Fig. 3c) . Subgroup analyses based on initiation of statins showed that both prediagnosis (n 5 31; HR 0.74, 95% CI, 0.68 to 0.79) and postdiagnosis statin use (n 5 24; HR 0.65, 95% CI, 0.60 to 0.72) were significantly associated with reduced ACM (Fig. 3a) . Although patients of postdiagnosis statin use had lower ACM than those of prediagnosis, statistically significant difference was not noted (p 5 0.133). Among studies including patients with different disease stages, the summary HRs for patients with nonmetastatic, metastatic and mixed (both metastatic and nonmetastatic) disease were 0.79 (95% CI, 0.72 to 0.87), 0.54 (95% CI, 0.30 to 0.98) and 0.67 (95% CI, 0.62 to 0.72), respectively (p for subgroup difference 5 0.017; Fig. 3b) .
Further subgroup analyses are demonstrated in Supporting Information Table S5A . Compared with the studies published in full text, studies published in abstract form tended to report lower HR for ACM (p for subgroup difference < 0.001). We also noted that studies with smaller sample size (200), singlecentered, conducted in Asia but non-European or nonAmerican regions tended to report lower HRs (All p values for subgroup difference < 0.05).
For ACM, the asymmetry of the contour enhanced funnel plot and Egger's linear regression test (p < 0.001) indicated the possible presence of publication bias (Supporting Information Fig. 1 ). The hollow circles in the funnel plot show the 13 missing studies that lay in the significant regions of the plot, suggesting that the asymmetry was not attributed mainly to publication bias, which was further confirmed by the Begg's rank correlation test (p 5 0.76). Sensitivity analysis revealed that no one particular study influenced the pooled estimate in the meta-analysis performed for ACM (Supporting Information Fig. 2 ). The adjusted random effects summary HR of 0.84 (95% CI, 0.79 to 0.89) recalculated using the trim and fill method had the same trend as that of the primary analysis.
Cancer-specific mortality. Thirty-two studies involving 1,018,604 individuals investigated the association between statin use and CSM. The combined HR was 0.60 (95% CI, 0.47 to 0.77), among which prostate cancer (n 5 12; HR 0.43, 95% CI, 0.25 to 0.76), colorectal cancer (n 5 7; HR 0.76, 95% CI, 0.69 to 0.83) and breast cancer (n 5 6; HR 0.74, 95% CI, 0.58 to 0.96) were three commonest types of cancer involved. Subgroup analyses showed that both prediagnosis (n 5 18; HR 0.62, 95% CI, 0.53 to 0.73) and postdiagnosis statin use (n 5 12; HR 0.65, 95% CI, 0.55 to 0.76) were significantly associated with reduced CSM, but with similar survival impact (p for subgroup difference 5 0.777).
Significant decrease in CSS was noted among studies including patients with mixed disease (HR 0.60; 95% CI, 0.53 to 0.69), but not with nonmetastatic (HR 0.65; 95% CI, 0.34 to 1.25) or metastatic disease (HR 0.58; 95% CI, 0.30 to Cancer Epidemiology T&F: result of trimmed and filled analysis, using assumption of random effects; het: heterogeneity. Fill: number of studies added by trim and fill method. Table S5C ).
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No evidence of publication bias was indicated based on Begg's rank correlation test (p 5 0.96) and Egger's linear regression test (p 5 0.10). The trim and fill method by imputed three missing studies and the adjusted pooled estimate was 0.79 (95% CI, 0.64 to 0.96), which is simalar to our original risk estimate.
Recurrence-free survival. Thirty-four studies involving 59,732 individuals explored the association between statin Table S5D ).
Egger's linear regression test (p 5 0.033) indicated potential evidence of publication bias. Therefore, we used trim and fill method to recalculate the summary estimate and the imputed pooled HR was 0.82 (95% CI, 0.72 to 0.94), which does not alter the original result when four missing studies were imputed. Progression-free survival. Twenty-two studies involving 32,868 individuals investigated the association between statin use and PFS. The summary HR was 0.67 (95% CI, 0.56 to 0.81), among which prostate cancer (n 5 9; HR 0.59, 95% CI, 0.47 to 0.74), breast cancer (n 5 3; HR 0.66, 95% CI, 0.44 to 1.00) and renal cancer (n 5 3; HR 0.85, 95% CI, 0.68 to 1.29) were three commonest types of cancer involved.
Subgroup analyses indicated that both prediagnosis (n 5 11; HR 0.65, 95% CI, 0.49 to 0.88) and postdiagnosis statin use (n 5 8; HR 0.73, 95% CI, 0.60 to 0.91); metastatic (n 5 2; HR 0.79, 95% CI, 0.68 to 0.92), nonmetastatic (n 5 13; HR 0.68, 95% CI, 0.57 to 0.81) and mixed (n 5 9; HR 0.65, 95% CI, 0.43 to 0.98) disease were all significantly associated with longer PFS, but with similar survival impact (p for subgroup difference both > 0.05) (Supporting Information Table S5E ).
No evidence of publication bias was indicated based on Begg's rank correlation test (p 5 0.96) and Egger's linear regression test (p 5 0.10). The trim and fill method by imputed three missing studies and the adjusted pooled estimate was 0.79 (95% CI, 0.64 to 0.96), which is simalar to our original risk estimate. 
Discussion
Principal findings
This systematic review and meta-analysis of 95 studies involving over 18 cancer types with a total of 1,111,407 patients provides consistent evidence of an association between statin use and reduced ACM, an association that persisted for CSM, PFS, RFS and DFS. These associations almost remained consistent for ACM, CSM and RFS when stratified by publication type, tumour location, study design, sample size, initiation of statins, disease stage, research region, follow-up duration or research hospital involved. As inhibitors of 3-hydroxy-3-methyglutaryl coenzyme A (HMGCoA) reductase in the mevalonate pathway, statins play an pivotal role in reducing blood cholesterol levels and as standard medication for the prevention of cardiovascular disease in people at risk. 113 However, the exact mechanism that explains the improved survival outcomes for cancer patients who take statins has not been clearly elaborated. Current evidence for the potential antineoplastic mechanisms of statins might due to the following reasons: inhibiting the cancer cell proliferation, angiogenesis and migration by systemic cholesterol reduction 114, 115 ; inducing apoptosis through phosphorylation of Akt and down-regulation of mammalian target of rapamycin (mTOR), stimulating antitumour immune surveillance and inflammatory reaction. [116] [117] [118] Strength and limitations of our study Our study indicates that statin therapy for individuals diagnosed with cancer is strongly associated with improved cancer mortality and progression, even after stratification by initiation of statins or other variables. Before our study, a literature search through May 2015 found a recently published meta-analysis that was in line with this findings. 119 However, compared with ours, the previous published meta-analysis focused mainly on two survival outcomes (ACM and CSM) without cancer recurrence or progression information reported and did limited number of subgroup analyses. Our findings still do not demonstrate the direct causal association whether statin use is directly linked to improved survival or whether it can serve as a prognostic marker for cancer outcomes due to the nature of observational study. Despite this uncertainty, the results have major clinical implications and provide promising evidence for the additional recommendations of adjuvant cancer treatment approach besides chemoradiotherapy before the confirmation from randomized clinical trials done in cancer patients. Besides the consistent findings, our study included a larger number of studies as well as sample size, more detailed survival outcomes, more comprehensive subgroup analyses and assessment of study quality. To the best of our knowledge, this is the first metaanalysis to comprehensively summarize results for the relationship between statin use and cancer mortality and progression with the largest population to date. In addition, we also stratified survival outcomes in studies with different publication type, tumour location, study design, initiation of statins, disease stage, sample size, study region, follow-up period and hospital involved. Our findings are further supported by three meta-analyses that reported reduced risk of ACM or CSM in patients with colorectal cancer 120, 121 and breast cancer 42 who took regular statins before or after diagnosis of cancer.
Besides, several other important strengths existed in our meta-analysis. First, we developed systematic, comprehensive and reproducible search strategies of the major databases combined with manual reference search of some of the important journals on oncology for all relevant papers published with no language limitations, enabling us to minimize bias for our meta-analysis. Second, the largest sample size of >1,110,000 included patients provided the most powerful and comprehensive synthesis of the evidence so far concerning the impact of the statin use on cancer mortality and progression. Third, relative thorough stratified analyses were performed across studies, and generally unanimous result was drawn, despite the heterogeneity in study characteristics. Fourth, all the included studies were formally assessed and rated the study quality or risk of bias using a commonly used scale for prognosis research, 122 and multiple approaches, such as trim and fill method, were applied to assess the publication bias.
Still some limitations of our study need to be addressed. First, it is indicated by the I 2 statistic that considerable heterogeneity was noted in the meta-analysis. This is predictable as major differences do exist among studies in the study design (prospective and retrospective), enrolled populations, treatment regimen, duration of follow-up, outcome measures and other study characteristics-such heterogeneity could explain substantial differences in survival estimates and the associations observed. There are, however, other unneglectable limitations such as difference in type of statins, dose,duration in the use of statins and adherence to taking statins. Different statin types (lipophilic statins and hydrophilic statins) and different doses of statins may have different effects on cancer prognosis. 42, 119, 123 However, this associations should be interpreted with caution due to the data analysed from limited studies in mixed cancer types. Furthermore, we could not perform subgroup analyses to investigate whether stains would have less or greater effect on patients suffering from concomitant hyperlipidemia due to unavailability of such data. As a study level meta-analysis instead of individual patient data meta-analysis, these data could not be obtained from the majority of included studies for subgroup analysis. Second, potential publication bias is suggested by funnel plot asymmetry for major outcome as ACM, though this was observed in a small proportion of all patients (18%) and the survival association remained consistent when the results were adjusted by the trim and fill method. Third, the included studies applied various survival analysis methods which might have to some extent affected the accuracy and precision of the pooled estimates. Although the multivariate Cox proportional hazards model was the most frequently employed method in survival analysis, the confounding covariates varied between studies. For those studies without multivariate analysis data, univariate analysis was applied. Four, we could not perform more detailed subgroup analyses related to specific tumour stage (e.g., stages I, II, III and IV, separately), some important molecular pathological features such as KRAS, BRAF, PIK3CA, BRCA or IDH mutation, microsatellite instability status, CpG island methylator phenotype, LINE-1, DNA methylation, microRNA expression and other influential factors due to unavailability of subgroup data in the included studies. Moreover, some of these factors have been identified to be associated with cancer patient survival. Five, we did not contact the authors of some included studies with insufficient analytical data. Although we used the method provided by Tierney et al. 44 and Parmar et al. 45 to pool the estimates, such procedure might have affected the precision of the pooled estimates, thus leading to certain bias. Moreover, our search database did not cover grey literature which could overestimate the treatment effect. 124 However, we are confident to have captured all relevant peer reviewed literature. Finally, due to lack of original information for some of the studies published in abstract form that had not gone through peer review, the risk of bias could not be adequately assessed.
Regarding the meta-analysis for ACM, though substantial inherent heterogeneity was observed, sensitivity analyses revealed that exclusion of any of the included study did not alter the trend of the pooled estimate. When the trim and fill model was applied by imputing 13 hypothesed studies, the results remained constant with our primary analyses, indicating publication bias did not largely alter our analyses. This association persisted for other investigated outcomes.
However, still caution is warranted when interpreting the association of statin use with cancer mortality and progression, because publication bias is inevitable and the current statistical methods for testing publication bias are quite limited.
This study provides the first robust statistical evidence for substantial prognostic significance of stain use in cancer patients. Although several published studies demonstrated null prognostic association of statin use in cancer patients, the final number of included studies is small in several outcome measures and many of them contained limited sample sizes, which could not provide sufficient statistical power for these studies. It is well known that studies with smaller sample size may result in false positive estimates of effect sizes for any association, and generating publication bias.
We also note that postdiagnosis statin users have more favorable survival benefits than prediagnosis statin users, mainly for RFS. One explaination lies in that, as Alexandre et al. have reported, 123 prediagnosis statin users are more likely to be older individuals who have cardiovascular diseases or diabetes and these individuals are mostly overweight and smokers, compared with postdiagnosis statin users. All these features might partly contribute to the poorer prognosis for prediagnosis statin users than postdiagnosis statin users. However, we only noted this association for RFS. Therefore, further study should be conducted on this issue.
Conclusions and implications for practice
It has been reported that several important adverse events or side effects are attributed to statin use. It seems that individuals with statin use have a higher rate of developing diabetes, asymptomatic increase in liver enzymes and muscle-related symptoms. [124] [125] [126] [127] [128] Despite all these side-effects, our study has significant clinical implications. High blood cholesterol level is a common status in a broad sample of patients diagnosed with cancer who take statins and statin use is strongly associated with decreased mortality and improved cancer progression, even after adjustment for initiation of statins or some other variables. We consider that in future research, large prospective studies or individual patient data meta-analyses are advocated to minimize the confounders of the baseline characteristics, especially in specific cancer types; besides, although a definite proof of statins on cancer mortality and progression, current evidence lacks further trials considering dose and duration response of statin use.
